2022
DOI: 10.1007/s11886-022-01800-7
|View full text |Cite
|
Sign up to set email alerts
|

Role of Sex in Atherosclerosis: Does Sex Matter?

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
2

Citation Types

1
6
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
5

Relationship

0
5

Authors

Journals

citations
Cited by 9 publications
(7 citation statements)
references
References 91 publications
1
6
0
Order By: Relevance
“…There are also well-known sex differences in atherosclerotic burden, where women have a known lower prevalence, possibly due to protective effect of oestrogen before menopause. 45 This has also previously been reported in SCAPIS. 46 …”
Section: Discussionsupporting
confidence: 79%
“…There are also well-known sex differences in atherosclerotic burden, where women have a known lower prevalence, possibly due to protective effect of oestrogen before menopause. 45 This has also previously been reported in SCAPIS. 46 …”
Section: Discussionsupporting
confidence: 79%
“…A total of 2.1% (n = 7/336) of patients with right-sided endocarditis had pulmonary MA, with none developing extrathoracic aneurysms (data not shown); this corresponds to the logical spread of embolisms to right-side circulation. On the other hand, the higher burden of atherosclerotic peripheral arteriopathy in male patients could explain the higher proportion of extracranial MA in this subgroup [ 29 , 30 ]. Finally, Candida spp.…”
Section: Discussionmentioning
confidence: 99%
“…Cardioprotective effects of estradiol and progesterone have been studied in general populations; however, little is known about how sex hormones influence cardiovascular physiology among individuals with PTSD. Studies in general populations show that circulating estradiol and progesterone play a role in lowering BP via vasodilation, upregulation of low density lipoprotein (LDL) receptors to help lower cholesterol, promotion of endothelial repair after vascular injury, and the slowing of cardiac hypertrophy (Niță et al, 2021 ; Palmisano et al, 2017 ; Regitz-Zagrosek & Kararigas, 2017 ; Trivedi et al, 2022 ; Xue et al, 2014 ). Randomised controlled clinical trials have shown that starting hormone replacement therapy with synthetic estradiol and progestin in early post-menopausal women led to significantly decreased risk of myocardial infarction and heart failure at 10 years follow-up, as well as slowed progression of atherosclerosis (Hodis et al, 2016 ; Schierbeck et al, 2012 ).…”
Section: Introductionmentioning
confidence: 99%